By Colin Kellaher

Ligand Pharmaceuticals Inc. (LGND) Monday said it signed a worldwide license agreement for its OmniAb antibody discovery platform with Paris drug maker Sanofi S.A. (SAN.FR, SNY).

The San Diego biopharmaceutical company said Sanofi will pay an undisclosed upfront platform access fee, along with development and regulatory milestone payments and potential royalties on sales of marketed products.

Ligand said it has licensed OmniAb to more than 40 companies around the world.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 02, 2019 11:59 ET (16:59 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Sanofi
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Sanofi